Pricing Transparency debate at World Health Assembly May 2019

A vigorous debate is occurring at the WHA in Geneva over the need for R&D cost transparency leading to availability of medicines at affordable prices.  Italy has submitted a resolution that is supported by some, modified by others and opposed by others. Detailed analyses of what is happening has been provided and can be seen here

  • Italy submits drug pricing transparency resolution to WHO
  • Italy and 11 co-sponsors introduce transparency resolution text to WHA72
  • Improving the transparency of markets for medicines, vaccines, and other health-related products and other technologies to be discussed at the 72nd session of the WHA to be held on 20-28 May 2019
  • Push for drug pricing transparency strikes a nerve with industry
  • Side event: Health Policy Watch: Several Ministers Of Health Speak Up For Drug Market Transparency, Lower Prices At WHA Side Event
  • Clinical trials: Roche and Novartis neglect their ethical responsibility in emerging countries
This entry was posted in Uncategorized. Bookmark the permalink.